Pharmacogenomics (PGx), the study of a patient’s response to medications relative to their genetics, is a rapidly expanding component of precision medicine. The ability to look at an individual’s DNA/genetics and use that information along with all other pertinent data, to guide drug and/or drug dose selection can lead to more successful treatment, and help reduce adverse drug events. Approximately 50 percent of patients receiving particular medications do not respond optimally. Additionally, over the last number of years, we have seen an increase in the number of serious adverse drug events, with more than 1,000,000 serious events and more than 180,000 deaths annually. Along with other patient information, there is a role for pharmacogenomics in helping to improve and optimize patient medication therapy.
With the launch of the nation’s first master’s program in pharmacogenomics (PGx) in 2016, Manchester University acted upon the need to educate applied scientists and clinicians in PGx. The Master of Science in Pharmacogenomics Program is a comprehensive program aimed at producing the applied scientist with opportunities for careers in the PGx laboratory industry, translational companies, and health care systems. The Graduate Certificate in Pharmacogenomics, introduced in 2020, is aimed at clinicians, such as pharmacists, physicians, nurse practitioners, physician assistants, and others, to help them optimize drug therapy and hone their pharmacotherapy expertise. As the clinical application of PGx is expanding, such as the launch of the Veterans Administration system PGx program that includes hiring more than 100 pharmacists for PGx dissemination, PGx education is imperative. Check out our Higher Learning Commission-approved programs (MS in PGx on-campus, MS in PGx online, and GC in PGx online) and contact us with any questions.